Disease targets also act as tumor suppressors

Two studies published in the last week suggest that strategies to treat disease, including inhibiting targeting PD-1 or protein tyrosine phosphatase 1B (PTP-1B; PTPN1), can also lead to cancer.

PD-1 inhibitors like Keytruda pembrolizumab from Merck & Co. Inc.